MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202541124438 A) filed by Saveetha Institute Of Medical And Technical Sciences, Chennai, Tamil Nadu, on Dec. 10, 2025, for 'novel triple combination hair serum containing nanoformulations of dutasteride 0.0025% melatonin 0.1 redensyl 3% for androgenic alopecia.'
Inventor(s) include B. Thayasre; Dr Rajesh Kumar; Deepak Nallaswamy; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "Androgenetic alopecia (AGA) is a progressive hair loss disorder that affects both men and women, often resulting in reduced self-esteem and psychosocial distress. Conventional therapies such as oral finasteride, dutasteride, and topical minoxidil are widely used but frequently limited by modest efficacy, systemic side effects, or poor patient adherence, creating a need for safer and more effective alternatives. This study introduces a novel fixed-dose topical hair serum containing Dutasteride 0.025%, Melatonin 0.1 %, and Redensyl 3%, formulated to address multiple mechanisms implicated in AGA. Dutasteride acts as a dual 5-alpha reductase inhibitor, reducing dihydrotestosterone (DHT)-mediated follicular miniaturization. Melatonin provides antioxidant protection, counteracts oxidative stress, and prolongs the anagen (growth) phase of hair follicles. Redensyl, a regenerative complex, stimulates follicular stem cells and dermal papilla cells, thereby promoting hair regrowth and density. The integration of pharmaceutical and cosmeceutical components in a single topical preparation offers a synergistic approach that enhances efficacy while minimizing systemic absorption and side effects. The convenient serum formulation is designed to improve patient compliance compared to oral agents or complex regimens This novei-combination represents a promising;-multi-=targeted;-and compliance=friendly therapeutic option for the management of androgenetic alopecia."
Disclaimer: Curated by HT Syndication.
